[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2061953T3 - Un procedimiento para preparar una composicion farmaceutica. - Google Patents

Un procedimiento para preparar una composicion farmaceutica.

Info

Publication number
ES2061953T3
ES2061953T3 ES89202877T ES89202877T ES2061953T3 ES 2061953 T3 ES2061953 T3 ES 2061953T3 ES 89202877 T ES89202877 T ES 89202877T ES 89202877 T ES89202877 T ES 89202877T ES 2061953 T3 ES2061953 T3 ES 2061953T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
preparing
procedure
ring
sustit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89202877T
Other languages
English (en)
Inventor
Patrick Carlier
Andre Monteil
Claude Poisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of ES2061953T3 publication Critical patent/ES2061953T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA QUE ES UTIL COMO MEDICAMENTOS PARA EL TRATAMIENTO DE DESORDENES DEL SISTEMA NERVIOSO CENTRAL, CARACTERIZADO EN QUE CONTIENE EXCIPIENTES FARMACEUTICOS Y AL MENOS UNO DE LOS COMPUESTOS DE FORMULA (I) EN EL CUAL EL TRIFLUOROMETIL SUSTITUYENTE ESTA EN LA POSICION 4, EN LA POSICION 5 O EN AMBAS POSICIONES DEL ANILLO DE PIRIDINAL, Y EL SUSTITUYENTE R MUESTRA HIDROGENO O HALOGENO COMO CIORINA EN LA POSICION DEL ANILLO DE PIRIDINIL NO OCUPADO POR CF3 Y SUS SALES FARMACEUTICAMENTE ACEPTABLES.
ES89202877T 1988-11-24 1989-11-14 Un procedimiento para preparar una composicion farmaceutica. Expired - Lifetime ES2061953T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88402965 1988-11-24

Publications (1)

Publication Number Publication Date
ES2061953T3 true ES2061953T3 (es) 1994-12-16

Family

ID=8200442

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89202877T Expired - Lifetime ES2061953T3 (es) 1988-11-24 1989-11-14 Un procedimiento para preparar una composicion farmaceutica.

Country Status (12)

Country Link
US (1) US4971969A (es)
EP (1) EP0370560B1 (es)
JP (1) JP2873025B2 (es)
KR (1) KR0155543B1 (es)
AU (1) AU621419B2 (es)
CA (1) CA2003665C (es)
DE (1) DE68912282T2 (es)
DK (1) DK175313B1 (es)
ES (1) ES2061953T3 (es)
IE (1) IE62792B1 (es)
NZ (1) NZ231487A (es)
ZA (1) ZA898728B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE911774A1 (en) * 1990-06-11 1991-12-18 Akzo Nv Pyridinylpiperazine derivatives
JP2000513337A (ja) * 1996-06-06 2000-10-10 エルゴ・リサーチ・コーポレイション ドーパミン及びセロトニンアゴニストによる脂質及びグルコース代謝障害の治療
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
EP1027336B1 (en) 1997-10-27 2004-10-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
US20040038985A1 (en) * 2000-10-13 2004-02-26 Patrick Carlier Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
EP1213017A3 (en) * 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes
US6498184B2 (en) 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
SE0201544D0 (sv) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
MXPA05013365A (es) * 2003-06-20 2006-04-05 Arena Pharm Inc Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c.
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
CA2594987A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
JP4745446B2 (ja) * 2007-03-05 2011-08-10 エフ．ホフマン−ラ ロシュ アーゲー Ｇｌｙｔ−１阻害剤の合成
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5690060A (en) * 1979-12-24 1981-07-21 Ishihara Sangyo Kaisha Ltd 2-amino-trifluoromethylpyridine derivative and its preparation
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
FR2573075B1 (fr) * 1984-09-14 1987-03-20 Innothera Lab Sa Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique
CA1286672C (en) * 1985-10-16 1991-07-23 Magid A. Abou-Gharbia Fused bicyclic imides with psychotropic activity
FR2611713B1 (fr) * 1987-02-27 1990-11-30 Adir Nouveaux derives de l'acide (dihydro-2,3 oxo-2 benzofurannyl-3)-2 acetique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US4876256A (en) * 1988-04-29 1989-10-24 Merck & Co., Inc. Alkylpiperazinylpyridines as hypoglycemic agents

Also Published As

Publication number Publication date
JP2873025B2 (ja) 1999-03-24
AU621419B2 (en) 1992-03-12
ZA898728B (en) 1990-08-29
KR0155543B1 (ko) 1998-11-16
CA2003665C (en) 1999-04-06
DK587989A (da) 1990-05-25
CA2003665A1 (en) 1990-05-24
EP0370560B1 (en) 1994-01-12
DE68912282T2 (de) 1994-04-28
DK587989D0 (da) 1989-11-22
KR900007419A (ko) 1990-06-01
NZ231487A (en) 1991-01-29
AU4538789A (en) 1990-05-31
IE62792B1 (en) 1995-03-08
JPH02184672A (ja) 1990-07-19
US4971969A (en) 1990-11-20
EP0370560A1 (en) 1990-05-30
DK175313B1 (da) 2004-08-16
IE893654L (en) 1990-05-24
DE68912282D1 (de) 1994-02-24

Similar Documents

Publication Publication Date Title
ES2061953T3 (es) Un procedimiento para preparar una composicion farmaceutica.
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
ES2164889T3 (es) Semicarbazonas con actividad sobre el snc y preparados farmaceuticos a base de las mismas.
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
AR008853A1 (es) Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos
ES2139638T3 (es) 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas.
CY2123B1 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides drugs containing these compounds and use of such drugs
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
NO304595B1 (no) Terapeutisk aktive derivater av 1-naftylpyrazol-3-karboksamider, farmas°ytiske preparater inneholdende dem, og mellomprodukter for fremstilling av dem
NO942952L (no) 11-benzaldoksin-17 ater, fremgangsmåte for deres fremstilling samt legemiddel inneholdende slike
ATE137501T1 (de) Benzazin-verbindungen und deren pharmazeutische verwendungen
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
MX9300399A (es) Derivados heterotriciclicos.
ES2184089T3 (es) Derivados de 2,4 - diaminopirimidina.
KR920002151A (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
ES2058449T3 (es) Nuevas piperazinilalquil-3(2h)-piridazinonas, procedimiento para su obtencion y su empleo como agentes reductores de la presion sanguinea.
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
ES2134284T3 (es) Pirido-pirimidindionas, procedimiento para su preparacion y su empleo como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 370560

Country of ref document: ES